Objective 
Introduction

Current evidence indicates that combination therapy of peginterferon and ribavirin for HCV is associated with higher rate of sustained virological response (SVR) compared with IFN alone (1-3). Thus, combination therapy of peginterferon and ribavirin for HCV has been recommended as a first choice for chronic hepatitis C.
However, IFN therapy has been associated with various IFN-related adverse events, such as psychological disturbances, poor appetite, skin rash, infection, anemia and leukopenia. In particular, the side effects in patients receiving combination therapy are more common than receiving IFN monotherapy patients (1) (2) (3) (4) (5) (6) . Thus, dose reduction or even discontinuation of treatment becomes necessary. Schalm et al (7) has reported that none of the patients who discontinued therapy achieved a sustained response, and adherence to combination therapy enhanced sustained virological eradication in genotype 1 with chronic hepatitis C (8) (9) (10) . Thus, in this present study, we assessed the incidence of discontinuation induced by side effects of combination therapy in Japanese patients in a nonrandomized prospective cohort study. (12) . HCV-genotype was examined by polymerized chain reaction assay, using a mixture of primers for the six subtypes known to exist in Japan, as reported previously (13) . (14) . 
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Discontinuation in combination therapy
Of the 612 patients originally included in this study, 68 discontinued the combination therapy owing to the following adverse events: that is, 17 cases of psychological disorders, 15 cases of general fatigue, six cases of eruption with itching, five cases of anemia, four cases of poor appetite, three cases of thrombocytopenia, two cases each of aggravation of diabetes mellitus, aggravation of ALT, vertigo, pneumonia, retinopathy, diagnosis of malignant tumor, hypothyroid, and one case each of arrhythmia, headache, bone fracture, retinal bleeding.
The cumulative discontinuation rate due to adverse events of therapy was 8.4% at 0.5 year, 14.9% at one year (Fig. 1) 
The efficacy after discontinuation of combination therapy
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hand, when the percentage of each medication actually taken during treatment was <60%, SVR was 7.7% (3/39 (2, 3, 5) . As for discontinuation in general, the present study is almost the same as those described before. The current study demonstrated that the discontinuation rate was as high as 30% in patients with !60 years old, and patient age was significantly associated with adherence to combination therapy (6) . Thus, the combination therapy for elderly patients was closely monitored for indication of treatment and follow-up during treatment.
Secondly, in the discontinuous group, patients with adherence dose of <60% showed low SVR. Namely, discontinuation of <24 weeks in combination therapy reduces the SVR. Bronowicki et al (16) reported that discontinuing ribavirin permanently reduces SVR. Some authors have indicated that management of tolerance should be considered as an important problem for enhancing SVR (9, 10, 17 T a b l e 2 . P r e d i c t i v e F a c t o r s f o r Di s c o n t i n u a t i o n B a s e d o 
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taining the combination therapy to the extent of scheduled dose is necessary to get high SVR.
In combination therapy, patient age and patient complications are important factors contributing to the safety. In the discontinuation-group, patients who adhered >60% to the total scheduled dose tended to achieve a high SVR.
